NEWS

AXOL BIOSCIENCE

MEA SCREENING

Axol Bioscience has expanded its service offering with the introduction of multi-electrode array (MEA) screening for human induced pluripotent stem cell (hiPSC)-derived cells.

The new services have been developed to support pre-clinical research by optimising hiPSC-derived cell culture, while providing high-quality electrophysiological data acquisition and analysis from physiologically relevant human cell models.

→ axolbio.com

MOGRIFY

EX VIVO THERAPIES

Mogrify, a UK company aiming to transform the development of *ex vivo* cell therapies and pioneer the field of *in vivo* reprogramming therapies, has announced the introduction of EpiMOGRIFY.

The platform models the epigenetic state of the cell to predict the switches important for cell identity, cell maintenance,

directed differentiation and cell conversion.

It is an extension of the company's proprietary direct cellular conversion technology MOGRIFY.

→ mogrify.co.uk



LGC

SARS-COV-2 SOLUTIONS

LGC's SeraCare has expanded its line of SARS-CoV-2 quality solutions to include products designed for use with multiplexed molecular assays that can detect SARS-CoV-2, influenza A/B and respiratory syncytial virus (RSV).

The AccuPlex SARS-CoV-2, Flu A/B and RSV Verification Panel is optimised for assay verification at installation by documenting test performance along the assay's range.

This enables labs to establish lower limits of detection, perform assay comparisons, and evaluate staff proficiency. The AccuPlex SARS-CoV-2, Flu A/B and RSV Reference Material Kit measures day-to-day assay performance, providing a positive and a negative reference solution.

→ seracare.com

